Mirikizumab (Omvoh)

Interleukin-23 antagonist (anti-interleukin)

Indications

Adults with moderate to severely active UC or CD who: who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment

Contraindications

Potential side effects: Nose and throat infection; joint pain; headache; opportunistic infection

Preparations Available

Intravenous infusion for induction; subcutaneous injection for maintenance

Quantity

UC dose: Induction up to week 8: 300mg every 4 weeks. Maintenance beyond week 8: 200mg every 4 weeks. CD dose: Induction up to week 8: 900mg every 4 weeks. Maintenance beyond week 8: 300mg every 4 weeks.

Price

300mg vial of concentrate solution for infusion (UC/CD), £2056.56
two-pack of 100mg per 1ml solution for subcutaneous injection (UC), £2056.56
200mg pre-filled pen and 100mg pre-filled pen for subcutaneous injection (CD), £2398.33